Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tobramycin

FDA-approved product (solution/drops, ophthalmic), marketed as Aktob, Bethkis, Kitabis Pak and 8 more.

Registered studies
50+
Lab records
48
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Tobramycin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Allergic conjunctivitis
  • Bacterial disease
  • Cystic fibrosis
  • Eye infection
  • Infection
  • Inflammation
  • Respiratory tract infectious disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other aminoglycosides; Antibiotics
FDA pharmacologic class
Aminoglycoside Antibacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01GB01; WHO ATC S01AA12; FDA class Aminoglycoside Antibacterial

Repurposing investigation

Tobramycin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA4.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli4.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae51.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis66.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 3 of 10 lab records
  • E. coli: measured active in 6 of 15 lab records
  • K. pneumoniae: measured active in 17 of 23 lab records
Open Tobramycin in ChEMBL Registered studies below
Show the 48 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tobramycin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Fluorometholone Study

    NCT07308938 · start 2026-10-31

    Registered record
    Registry ID
    NCT07308938
    Conditions
    Keratitis Bacterial; Corneal Ulcer (Diagnosis)
    Interventions
    Adjunctive Topical Fluorometholone (FML) 0.1%; Standard Topical Antibiotic Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-10-31
    Completion
    2030-12-31
    Enrolment
    174

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKeratitis Bacterial; Corneal Ulcer (Diagnosis)
    InterventionAdjunctive Topical Fluorometholone (FML) 0.1%; Standard Topical Antibiotic Therapy
    PhasePhase 2
    Registry statusNot yet recruiting

  • Local Antibiotic Concentrations With Tissue Expanders in Breast Reconstruction

    NCT07339215 · start 2026-07-01

    Registered record
    Registry ID
    NCT07339215
    Conditions
    Tissue Expander Based Breast Reconstruction
    Interventions
    Antibiotic loaded calcium sulfate beads; Polymethylmethacrylate antibiotic disc
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-07-01
    Completion
    2027-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTissue Expander Based Breast Reconstruction
    InterventionAntibiotic loaded calcium sulfate beads; Polymethylmethacrylate antibiotic disc
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Microbiome-guided Prophylaxis to Reduce Ventilator-Associated Pneumonia in Intensive Care Units: A Pilot Randomized Controlled Trial

    NCT07463339 · start 2026-05-01

    Registered record
    Registry ID
    NCT07463339
    Conditions
    Critical Illness; Mechanical Ventilation
    Interventions
    Microbiome-guided inhaled antibiotic prophylaxis; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-05-01
    Completion
    2028-04-30
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCritical Illness; Mechanical Ventilation
    InterventionMicrobiome-guided inhaled antibiotic prophylaxis; Placebo
    PhasePhase 2
    Registry statusNot yet recruiting

  • Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis

    NCT06093191 · start 2023-10-18

    Registered record
    Registry ID
    NCT06093191
    Conditions
    Bronchiectasis Adult; Pseudomonas Aeruginosa Infection
    Interventions
    Tobramycin Inhalant Product; Ciprofloxacin 750 MG; Oral ciprofloxacin placebo; Natural saline inhalation
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2023-10-18
    Completion
    2025-11-15
    Enrolment
    371

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBronchiectasis Adult; Pseudomonas Aeruginosa Infection
    InterventionTobramycin Inhalant Product; Ciprofloxacin 750 MG; Oral ciprofloxacin placebo; Natural saline inhalation
    PhasePhase 4
    Registry statusCompleted

  • Short Antibiotic Treatment in High Risk Febrile Neutropenia

    NCT05786495 · start 2023-10-01

    Registered record
    Registry ID
    NCT05786495
    Conditions
    Febrile Neutropenia
    Interventions
    Early Discontinuation of Antibiotics; Standard of Care
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-10-01
    Completion
    2026-02-28
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFebrile Neutropenia
    InterventionEarly Discontinuation of Antibiotics; Standard of Care
    PhaseNot applicable
    Registry statusUnknown

  • Platelet-rich Fibrin(PRF) Membrane in Ophthalmic Diseases

    NCT06200727 · start 2023-01-01

    Registered record
    Registry ID
    NCT06200727
    Conditions
    Platelet-rich Fibrin; Macular Holes; Pterygium; Glaucoma
    Interventions
    PRF membrane tamponade surgery in macular hole; ILM peeling in macular hole; PRF membrane grafting in pterygium; Autologous conjunctival transplantation in pterygium; autologous PRF membrane grafting in trabeculectomy for glaucoma; Amniotic membrane in trabeculectomy for glaucoma; PRF membrane grafting incorneal ulcer; Amniotic membrane in corneal ulcer
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-01-01
    Completion
    2025-12-31
    Enrolment
    170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlatelet-rich Fibrin; Macular Holes; Pterygium; Glaucoma
    InterventionPRF membrane tamponade surgery in macular hole; ILM peeling in macular hole; PRF membrane grafting in pterygium; Autologous conjunctival transplantation in pterygium +4 more
    PhaseNot applicable
    Registry statusUnknown

  • Telemedicine Optimized Burn Intervention

    NCT05019144 · start 2022-06-01

    Registered record
    Registry ID
    NCT05019144
    Conditions
    Burns; Pediatric ALL
    Interventions
    Face-to-face burn care; Telemedicine enhanced burn care
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-06-01
    Completion
    2024-03-08
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBurns; Pediatric ALL
    InterventionFace-to-face burn care; Telemedicine enhanced burn care
    PhaseNot applicable
    Registry statusCompleted

  • Effect of Various Treatment Modalities on Dendritic Vial Ulcer

    NCT05313828 · start 2022-03-18

    Registered record
    Registry ID
    NCT05313828
    Conditions
    Corneal Ulcer
    Interventions
    Acyclovir; Tobramycin; Fluorometholone; Sodium Hyaluronate
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2022-03-18
    Completion
    2022-07-20
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCorneal Ulcer
    InterventionAcyclovir; Tobramycin; Fluorometholone; Sodium Hyaluronate
    PhaseNot recorded
    Registry statusUnknown

  • Safety and Efficacy of Thermosensitive Hydroxybutyl Chitosan and 5-fluorouracil Assisted Endoscopic Dacryocystorhinostomy in the Treatment of Chronic Dacryocystitis

    NCT06175676 · start 2021-12-03

    Registered record
    Registry ID
    NCT06175676
    Conditions
    Dacryocystorhinostomy; Hydroxybutyl Chitosan; Fluorouracil; Chronic Dacryocystitis
    Interventions
    Hydroxybutyl chitosan; 5-Fluorouracil; Gelatin Sponge Sheet
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-12-03
    Completion
    2023-12-03
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDacryocystorhinostomy; Hydroxybutyl Chitosan; Fluorouracil; Chronic Dacryocystitis
    InterventionHydroxybutyl chitosan; 5-Fluorouracil; Gelatin Sponge Sheet
    PhasePhase 1
    Registry statusCompleted

  • Topical Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: TOBRA

    NCT04597008 · start 2021-06-18

    Registered record
    Registry ID
    NCT04597008
    Conditions
    Post Operative Surgical Site Infection
    Interventions
    Treatment group; Control group
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-06-18
    Completion
    2025-07-30
    Enrolment
    1,660

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost Operative Surgical Site Infection
    InterventionTreatment group; Control group
    PhasePhase 3
    Registry statusCompleted

  • Acute Application of Antibiotic Powder in Open Fracture Wounds

    NCT04872400 · start 2021-06-14

    Registered record
    Registry ID
    NCT04872400
    Conditions
    Fractures, Open; Wounds and Injuries--Infections; Anti-Bacterial Agents; Fractures, Bone; Extremity Fracture Lower; Extremity Fractures Upper
    Interventions
    Vancomycin; Tobramycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-06-14
    Completion
    2023-09-30
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFractures, Open; Wounds and Injuries--Infections; Anti-Bacterial Agents; Fractures, Bone +2 more
    InterventionVancomycin; Tobramycin
    PhasePhase 4
    Registry statusCompleted

  • Implantable Phakic Lens (IPCL) VS Implantable Collamer Lens

    NCT04624035 · start 2020-10-10

    Registered record
    Registry ID
    NCT04624035
    Conditions
    Myopia
    Interventions
    Implantable Collamer Lens (ICL) in treatment of myopia in adults.; Implantable Intraocular Lens (IPCL) in treatment of myopia in adults.
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2020-10-10
    Completion
    2021-10
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyopia
    InterventionImplantable Collamer Lens (ICL) in treatment of myopia in adults.; Implantable Intraocular Lens (IPCL) in treatment of myopia in adults.
    PhaseNot applicable
    Registry statusUnknown

  • Cyclosporine 0.05% Eye Drops for Vernal Keratoconjunctivitis Trial

    NCT05353101 · start 2020-07-01

    Registered record
    Registry ID
    NCT05353101
    Conditions
    Vernal Keratoconjunctivitis; Cyclosporine 0.05% Eye Drops
    Interventions
    Cyclosporine 0.05% eye drops; Loteprednol Etabonate 0.5% and Tobramycin Eye Drops 0.3%
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-07-01
    Completion
    2021-06-01
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVernal Keratoconjunctivitis; Cyclosporine 0.05% Eye Drops
    InterventionCyclosporine 0.05% eye drops; Loteprednol Etabonate 0.5% and Tobramycin Eye Drops 0.3%
    PhasePhase 1
    Registry statusCompleted

  • Effect of Topical Sinonasal Antibiotics

    NCT03935828 · start 2019-06

    Registered record
    Registry ID
    NCT03935828
    Conditions
    Chronic Rhinosinusitis (Diagnosis); Antibiotic Side Effect
    Interventions
    Oral versus topical antibioitics
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2019-06
    Completion
    2021-06
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Rhinosinusitis (Diagnosis); Antibiotic Side Effect
    InterventionOral versus topical antibioitics
    PhasePhase 2
    Registry statusWithdrawn

  • Tobramycin Administered at the Beginning of Dialysis

    NCT03904836 · start 2019-01-31

    Registered record
    Registry ID
    NCT03904836
    Conditions
    Renal Dialysis; Renal Failure, Chronic
    Interventions
    Tobramycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-01-31
    Completion
    2019-12-31
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Dialysis; Renal Failure, Chronic
    InterventionTobramycin
    PhasePhase 1
    Registry statusCompleted